X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
venetoclax (312) 312
index medicus (141) 141
oncology (120) 120
hematology (115) 115
ibrutinib (108) 108
humans (87) 87
leukemia (83) 83
apoptosis (77) 77
open-label (75) 75
chronic lymphocytic leukemia (74) 74
chronic lymphocytic-leukemia (69) 69
cancer (68) 68
idelalisib (65) 65
bcl-2 (61) 61
cll (55) 55
chemotherapy (50) 50
abt-199 (47) 47
rituximab (47) 47
pharmacology & pharmacy (39) 39
proteins (39) 39
care and treatment (36) 36
lymphomas (36) 36
leukemia, lymphocytic, chronic, b-cell - drug therapy (34) 34
resistance (32) 32
acute myeloid leukemia (30) 30
proto-oncogene proteins c-bcl-2 - antagonists & inhibitors (30) 30
inhibitor (29) 29
therapy (29) 29
survival (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
hemic and lymphatic diseases (27) 27
medicine & public health (26) 26
previously untreated patients (26) 26
aml (24) 24
chronic lymphatic leukemia (24) 24
female (24) 24
acute myeloid-leukemia (23) 23
bcl2 (23) 23
initial therapy (23) 23
antitumor-activity (22) 22
patients (22) 22
research (22) 22
analysis (21) 21
bridged bicyclo compounds, heterocyclic - therapeutic use (21) 21
expression (21) 21
sulfonamides - therapeutic use (21) 21
animals (20) 20
antineoplastic agents - therapeutic use (20) 20
bcl-2 protein (20) 20
fludarabine (20) 20
lymphocytes b (20) 20
multicenter (20) 20
17p deletion (19) 19
health aspects (19) 19
lymphoma (19) 19
minimal residual disease (19) 19
mutation (19) 19
phase-i (19) 19
article (18) 18
review (18) 18
cell-death (17) 17
neoplasms. tumors. oncology. including cancer and carcinogens (17) 17
obinutuzumab (17) 17
antineoplastic agents - pharmacology (16) 16
clinical trials (16) 16
cyclophosphamide (16) 16
drug therapy (16) 16
lymphatic leukemia (16) 16
male (16) 16
multiple myeloma (16) 16
pharmacokinetics (16) 16
proto-oncogene proteins c-bcl-2 - metabolism (16) 16
usage (16) 16
diseases of the blood and blood-forming organs (15) 15
medical research (15) 15
phase-ii (15) 15
transplantation (15) 15
aged (14) 14
bcl-2 inhibitor (14) 14
immune system diseases (14) 14
mcl-1 (14) 14
molecular targeted therapy (14) 14
targeted therapy (14) 14
toxicity (14) 14
tumors (14) 14
abridged index medicus (13) 13
adult (13) 13
b-cell lymphoma (13) 13
bridged bicyclo compounds, heterocyclic - administration & dosage (13) 13
bridged bicyclo compounds, heterocyclic - pharmacology (13) 13
cancer therapies (13) 13
cell biology (13) 13
genetic aspects (13) 13
inhibition (13) 13
kinases (13) 13
middle aged (13) 13
navitoclax (13) 13
older patients (13) 13
sulfonamides - administration & dosage (13) 13
sulfonamides - pharmacology (13) 13
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (310) 310
Hungarian (3) 3
Spanish (3) 3
Polish (2) 2
Russian (2) 2
Croatian (1) 1
German (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 09/2019, Volume 16, Issue 9, pp. 526 - 527
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 02/2019, Volume 60, Issue 3, pp. 563 - 565
Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 12/2019, Volume 144, p. 102814
Leukemia stem cells (LSCs) have low levels of ROS and rely on mitochondrial integrity for their survival. In AML cells, ROS levels and stemness potential are... 
BCL-2 | Mitochondria | ROS | HSC | LSC | Autophagy | Venetoclax
Journal Article
Cancer research, ISSN 0008-5472, 6/2018, Volume 78, Issue 11, pp. 3075 - 3086
Inhibitors targeting BCL-2 apoptotic proteins have significant potential for the treatment of acute myeloid leukemia (AML); however, complete responses are... 
AML | GDC-0980 | BAX | BAK | Venetoclax | BIM
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2017, Volume 28, Issue 5, pp. 1050 - 1056
Background: Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their... 
ibrutinib | kinase inhibitor | CLL | idelalisib | venetoclax | THERAPY | MANAGEMENT | ONCOLOGY | OUTCOMES | ATRIAL-FIBRILLATION | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 32, pp. 22605 - 22617
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current chemotherapy is quite toxic in growing children and more directed... 
BCL-2 | Ruxolitinib | T-ALL | Venetoclax | JAK1
Journal Article
Oncogematologiya, ISSN 1818-8346, 2018, Volume 13, Issue 2, pp. 32 - 38
Journal Article
BLOOD, ISSN 0006-4971, 09/2016, Volume 128, Issue 10, pp. 1316 - 1317
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 102, p. 37777
Acute myeloid leukaemia (AML) cells often up-regulate pro-survival members of the BCL-2 protein family, such as BCL-2 and MCL-1, to avoid apoptosis. Venetoclax... 
Journal Article
TURKISH JOURNAL OF HEMATOLOGY, ISSN 1300-7777, 03/2019, Volume 36, pp. 15 - 16
Journal Article
LANCET HAEMATOLOGY, ISSN 2352-3026, 01/2019, Volume 6, Issue 1, pp. E8 - E9
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 15, pp. 1547 - 1548
In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab,... 
HEMATOLOGY | CYCLOPHOSPHAMIDE | FLUDARABINE | VENETOCLAX | RITUXIMAB
Journal Article
Cancer discovery, ISSN 2159-8274, 2/2017, Volume 7, Issue 2, pp. 156 - 164
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We... 
BCL-2 | leukemia | BPDCN | venetoclax | BH3 profiling
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 212, pp. 215 - 242
Over the last years, targeted anti-cancer therapy with small-molecule inhibitors and antibodies moved to the forefront as a strategy to treat hematological... 
BCL2 inhibitors | Venetoclax | Hematologic cancer
Journal Article
Blood, ISSN 0006-4971, 10/2018, Volume 132, Issue 15, pp. 1573 - 1583
Myeloid cell leukemia-1 (MCL-1) is a prosurvival B-cell lymphoma 2 (BCL-2) family member required for the sustained growth of many cancers. Recently, a highly... 
ANTI-APOPTOTIC MCL-1 | VENETOCLAX | BCL2 | LYMPHOMA | DRIVEN | CELL-SURVIVAL | HEMATOLOGY | DELETION
Journal Article
Oncotarget, ISSN 1949-2553, 06/2019, Volume 10, Issue 40, p. 4002
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.